Translating tumor biology insights into actionable genomic signatures of drug response and new targets.
GeneCentric’s Cancer rT(I)ME Explorer Platform builds on: 1) the pioneering tumor genomics work of co-founders, Charles Perou, PhD, and Neil Hayes, MD, MPH, MS, innovators in the molecular characterization and treatment of cancer and 2) the immunogenomic computational pipelines developed and curated by Benjamin Vincent, MD and Joel Parker, PhD. (founders of Select ImmunoGenomics; acquired by GeneCentric in 2019).
By applying rT(I)ME Explorer Platform technology, GeneCentric is expanding drug response biomarkers and identifying new targets to enable more effective and efficient drug development.
A keystone to drug response biomarkers and central to the rT(I)ME Explorer Platform are high resolution molecular subtypes – inherent genomic signal within a cancer type that is characteristic of its underlying biology. Through advanced computational biology, an expanding portfolio of cancer subtypes/biomarkers – what we call ‘Profilers’ – accrues within the rT(I)ME Explorer Platform.
rT(I)ME Explorer Platform leverages enormous, publicly available gene expression datasets complemented by proprietary data and tools to develop discrete sets of key genes that define cancer subtypes and predict drug response. By reducing the multitude of genes associated with response to discrete key gene set signatures, GeneCentric enables rapid development of tumor specific clinical assays. The signatures are ‘platform agnostic’, capable of being deployed on established commercial instruments.
GeneCentric’s ability to identify and reduce to practice a select set of genes that define cancer subtypes and predict drug response underlies the company’s core patents and proprietary position. Our intellectual property includes technology licensed from the University of North Carolina, based on technology developed by Drs. Perou and Hayes, as well as technology developed by GeneCentric.
In addition to core tumor biology subtypes -which often include characteristic immune profiles – a deep immunogenomic capability is essential to fully exploring the tumor in the context of its associated microenvironment. The rT(I)ME Explorer Platform is comprised of unparalleled immunogenomic pipelines involving diverse neoantigen prediction, highly curated and proprietary immune gene signatures and T cell and B cell (TCR/BCR) analysis capabilities. In addition to providing content for deriving predictive biomarkers, the immunogenomic component of the rT(I)ME Explorer Platform is a key target discovery enterprise; particularly with its neoantigen prediction capability.